Research centre director Professor Robert Tindle said RSV cost millions of dollars a year in health care in Australia and billions in the United States. It can lead to severe and lifethreatening lower respiratory tract infection or bronchiolitis.
About one in 1000 die from the illness. However, the vaccine that is being developed is expected to treat the illness in infected people as well as prevent against it.
Those most at risk from RSV are children aged two and under, especially those with weak respiratory symptoms, elderly people and the immunocompromised, such as people with HIV or those who have weakened immune systems due to treatments such as chemotherapy.
"Benefits of the vaccine will include a huge saving in health care costs," Professor Tindle said.
"(It will also) relieve the burden of worry on thousands of parents who every year go through all kinds of angst because their young children are going into hospital with very worrying symptoms and it would prevent the death of the children who succumb to it and die."
With preclinical modelling in mice having been encouraging, Professor Tindle said clinical trials were forthcoming, leading the way to the vaccine becoming available in the clinic. He hoped it would become one of the vaccines given to all infants in their first three months of life.
The mature paediatric market for an RSV vaccine has been estimated at approximately US$800 million (LeadDiscovery Ltd, 2004).
Professor Tindle said the importance of the research project was double-barrelled because, along with helping children, it included forming a new type of vac